Live Vital sells thirteen compounded treatments, each quoted by the month and billed for two months or ten weeks at a time, with a physician named on the site and a pharmacy that is not.

A menu that keeps changing

On 7 October 2026 the treatments page listed nine treatments on ten-week courses. On 14 October it listed four: compounded tirzepatide and semaglutide, NAD+ and glutathione. On 19 October it listed thirteen — the protocols that had gone came back, with BPC-157 and TB-500 added on their own. On 26 October the same thirteen carried new prices: up for most peptides (BPC-157 from $99 to $145 a month, MOTS-c from $149 to $200), down for NAD+ ($149 to $115), tesamorelin ($166 to $150) and glutathione ($99 to $95). Nothing on the site explains the changes.

A monthly figure, billed two months at a time

The peptides and NAD+ are now sold as two-month subscriptions: BPC-157 at $145 a month is $289 every two months, and the plan “renews automatically until you cancel”. Cancelling takes effect at the end of the current billing period. The two GLP-1s are still ten-week protocols: semaglutide at $99 a month is $299, tirzepatide at $183 is $549. Read the monthly figure as half or a third of what you pay at the start.

A price with no dose

Not one figure states a dose, a concentration or a vial size. NAD+ at $115 a month is a real number. Whether it is good value is not a question the site lets you answer, because you cannot tell how much NAD+ a month contains.

What the site does not say about payment

The refund page covers cancellation (effective at the end of the billing period) and dispensed medication (generally non-refundable). It does not say whether your card is charged before or after a clinician reviews the intake, or what happens to a payment if no prescription is issued; the terms of service refer to the refund page for exactly that, and on 26 October that place on the page held a bracketed note beginning “TODO” asking for it to be confirmed. Ask before you pay.

One half of the supply chain

Dr. Patrick Taylor, MD, is named as the physician behind the treatments. That is more than most sellers here offer.

The pharmacy is not named, only “a licensed 503A compounding pharmacy”. That matters more than it sounds, because the states page lists all fifty states, and it is the pharmacy’s non-resident licence that decides whether a compounded prescription can cross a state line. The clinician half of that claim can be checked in principle. The pharmacy half cannot be checked at all from what is published.

What is not here

Our own market survey in August recorded Live Vital as the first telehealth programme to put retatrutide on a public menu. It has not been on their treatments page on any date we have read it. We are not carrying it on the strength of our own note, and we are not claiming they withdrew it either — only that it is not there.